Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders

ClinicalTrials.gov ID: NCT00357305

Public ClinicalTrials.gov record NCT00357305. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 21, 2026, 6:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase I Study of Vorinostat (Suberoylanilide Hydroxamic Acid, or SAHA) in Combination With Cytosine Arabinoside (Ara-C) and Etoposide for Patients With Relapsed and/or Refractory Acute Leukemias, Myelodysplasias and Myeloproliferative Disorders

Study identification

NCT ID: NCT00357305
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1
Lead sponsor: National Cancer Institute (NCI); NIH
Enrollment: 25 participants

Conditions and interventions

Conditions

Interventions

vorinostat Drug
cytarabine Drug
etoposide Drug
pharmacological study Other
laboratory biomarker analysis Other

Drug · Other

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Apr 30, 2006
Primary completion: Oct 31, 2011
Completion: Not listed
Last update posted: May 2, 2013

Started 2006

United States locations

U.S. sites: 2
U.S. states: 2
U.S. cities: 2

Facility	City	State	ZIP	Site status
University of Maryland Greenebaum Cancer Center	Baltimore	Maryland	21201-1595	—
University of Pittsburgh	Pittsburgh	Pennsylvania	15232	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00357305, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted May 2, 2013 · Synced Jul 21, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00357305 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →